Financial Performance - The company's operating revenue for 2024 was ¥224,249,109.55, a decrease of 11.75% compared to ¥254,106,487.66 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥17,116,524.08, representing a significant increase of 109.26% from a loss of ¥184,907,769.73 in 2023[17]. - The cash flow from operating activities for 2024 was ¥34,258,202.60, a remarkable improvement of 191.97% compared to -¥37,249,852.89 in 2023[17]. - The total assets at the end of 2024 amounted to ¥1,457,165,935.92, reflecting a growth of 7.43% from ¥1,356,339,278.93 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.04, a turnaround from -¥0.46 in 2023, marking an increase of 108.70%[17]. - The company reported a weighted average return on equity of 1.99% for 2024, a significant recovery from -21.22% in 2023[17]. - The company’s net profit after deducting non-recurring gains and losses for 2024 was -¥1,778,814.32, an improvement of 99.08% from -¥193,906,931.05 in 2023[17]. - The company’s revenue after deducting certain amounts was ¥215,901,036.72 in 2024, compared to ¥248,939,445.80 in 2023[17]. - The company’s total net assets attributable to shareholders at the end of 2024 were ¥869,005,338.22, a slight increase of 2.36% from ¥848,993,883.06 at the end of 2023[17]. - The company’s quarterly revenue for Q4 2024 was ¥66,201,216.30, contributing to a total annual revenue of ¥224,249,109.55[19]. Dividend Distribution - The company plans to distribute a cash dividend of 0.1744 RMB per 10 shares to all shareholders, based on a total of 401,316,667 shares[3]. - The company has no plans for cash dividends, stock bonuses, or capital reserve transfers for the 2023 fiscal year[188]. Market and Industry Trends - The global food safety testing market is projected to reach $33.7 billion by 2028, with a compound annual growth rate (CAGR) of 8.2%[28]. - In China, the government has implemented a series of policies to enhance food safety, including the revised Food Safety Law, which supports rapid testing technologies[29]. - The 2021 "14th Five-Year" market supervision modernization plan emphasizes improving food safety testing capabilities and establishing a comprehensive food safety responsibility system[30]. - The new national standard for food additives (GB 2760-2024) imposes stricter regulations on the use of food additives, ensuring higher safety standards in food production[30]. - The rapid testing market is expected to grow significantly due to increasing government demand for food safety risk monitoring and testing[31]. - The implementation of the revised Agricultural Product Quality Safety Law enhances pre-market testing and strengthens regulatory oversight of agricultural products[30]. - The food safety testing market in China is driven by the need to address issues such as pesticide and veterinary drug residues, as well as food adulteration[29]. - The government is focusing on enhancing food safety in schools and promoting a comprehensive safety system from procurement to dining[30]. - The rapid testing technology is becoming increasingly integrated, automated, and focused on risk monitoring, improving the efficiency of food safety inspections[28]. - The market for rapid testing products is expected to expand as domestic testing technologies mature and standards are established[31]. Product Development and Innovation - The company has a focus on developing new products and technologies, although specific details are not provided in the current report[3]. - The company has developed a comprehensive food safety testing system covering various stages from feed to retail, ensuring food safety throughout the supply chain[35]. - The company’s rapid testing products include a high-throughput pesticide residue detection card capable of testing 16 pesticide residues simultaneously within 9 minutes[37]. - The animal diagnostics business includes a series of rapid pregnancy detection products for cattle and sheep, significantly enhancing farm economic efficiency[40]. - The company’s animal diagnostics products have received GMP certification and cover both economic and companion animals, with over 30 detection products for common pet diseases[39]. - The company’s food safety rapid testing instruments enable real-time data sharing and analysis, enhancing food safety monitoring capabilities[38]. - The company has established a "self-research and technology cooperation" model for product development, focusing on market-driven needs and combining government projects with industry-academia collaboration[41]. - The company has launched four microbial test products that significantly reduce testing time to approximately 18-24 hours, compared to the traditional 3-5 days[49]. - The company has developed a high-throughput pesticide residue rapid detection card that can simultaneously detect 16 types of pesticide residues within 9 minutes, significantly outperforming traditional enzyme inhibition methods[50]. - The company has improved the sample pre-treatment process, reducing it from a traditional five-step method to a two-step method, significantly shortening detection time[67]. Research and Development - The company has invested heavily in R&D, focusing on antigen-antibody self-manufacturing and efficient pre-treatment technologies, leading to a competitive edge in product quality and cost reduction[64]. - The total amount of research and development investment was ¥40,452,354.02, accounting for 18.04% of operating revenue[97]. - Research and development expenses decreased by 23.88% to ¥40,452,354.02, primarily due to the contraction of the in vitro diagnostic business[96]. - The company has obtained 11 new domestic invention patents, including a rapid detection method for penicillin in fruit and vegetable juices[83]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder rights, particularly for minority shareholders[144]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a diverse range of expertise and compliance with legal requirements[146]. - The company maintains independence from its controlling shareholders, with no interference in decision-making or operational activities[145]. - The company has a complete and independent business operation, with no competition or unfair transactions with controlling shareholders[152]. - The company has established a robust information disclosure system, ensuring timely and accurate communication with investors[149]. - The company has a dedicated financial department with an independent accounting system, ensuring financial autonomy[156]. - The company has a structured approach to remuneration that aligns with its operational status and legal regulations[170]. - The company has established a market value management system and is in the process of implementing a valuation enhancement plan[142]. - The company is committed to transparency, as shown by its detailed records of investor interactions available on the official website[139]. Employee Relations and Corporate Culture - The company has established a comprehensive training plan to enhance employee skills and core competitiveness[187]. - The company has a structured approach to employee recognition, including annual awards to enhance morale and corporate culture[186]. - The total number of employees at the end of the reporting period is 480, with 265 in the parent company and 215 in major subsidiaries[184]. - The company has a diverse professional composition, with 200 technical personnel, 107 sales personnel, and 99 production personnel[185]. - The company emphasizes a performance-oriented compensation policy, aiming to attract and retain talent with competitive salary packages[186]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and development strategies, as outlined in the management discussion section[3]. - The company has outlined potential risks and corresponding mitigation strategies in its future outlook section[3]. - The company acknowledges the risk of policy changes affecting the food safety testing industry and is focused on adapting to regulatory dynamics[135]. - R&D innovation risks are recognized, with a commitment to enhancing technological advancement and product quality to maintain competitiveness[136]. - The company emphasizes cost control and operational efficiency to mitigate the risk of declining gross margins in its main business[138]. Investor Relations - The company is actively expanding its investor relations activities, as evidenced by multiple scheduled communications throughout 2024[140]. - The company is focusing on enhancing its business conditions through regular updates and engagements with investors[141]. - The company plans to enhance its collaboration with large dairy enterprises and food production companies to increase its market share and develop new leading enterprise clients[54]. - The company has established several subsidiaries during the reporting period, including Inner Mongolia Yirui Biotechnology Co., Ltd., with no significant impact on overall operations[128]. Strategic Initiatives - The company is committed to advancing smart detection products to improve efficiency and compliance in food safety testing[133]. - A platform-based strategy will be implemented to integrate resources and meet diverse detection needs across various scenarios[134]. - The company is undergoing strategic adjustments, which led to the resignation of Deputy General Manager Gao Shitao on July 4, 2024[162]. - The company has appointed Jinlong Zhang as the new Deputy General Manager on July 4, 2024, as part of the strategic realignment[162].

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-008 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日收到控股股东 易瑞（海南）创业投资有限公司（以下简称"易瑞创投"）的通知，获悉其所持 有公司的部分股份办理了解除质押业务，具体事项如下： | 股东名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所持 | 占公司 总股本 | 质押起始日 | 解除质押 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份比例 | | | 日 | | | | 其一致行动人 | （股） | | 比例 | | | | | 易瑞（海南）创 | | | | | 2024 年 4 | 2025 年 4 | 深圳担保 | | 业投 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-007 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚 假记载、误导性陈述或重大遗漏。 二、股东股份质押的基本情况 1、本次股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所 | 占公司 | 是否 | 是否为 | 质押起始 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量 | 持股份 | 总股本 | 为限 | 补充质 | 日 | 期日 | 质权人 | 用途 | | | 一致行动人 | （股） | 比例 | 比例 | 售股 | 押 | | | | | | | | | | | | | | | 深圳市 | | | 易瑞（海 | | | | | | | | 办理解 | | | | | | ...

Core Viewpoint - The A-share and Hong Kong stock markets experienced significant declines, with major indices dropping over 2% to 3% amid ongoing market volatility and external pressures [2][3][5]. Market Performance - As of the report, the Shanghai Composite Index fell by 2.22% to 3075.75, while the Shenzhen Component Index dropped by 3.04% to 9138.12. The ChiNext Index also saw a decline of over 3% [2][3]. - In the Hong Kong market, the Hang Seng Index opened down by 3.81%, and the Hang Seng Tech Index fell by over 5%. Notably, the pharmaceutical and consumer sectors faced significant losses, with companies like Wan Zhou International and WuXi Biologics experiencing declines of nearly 10% and over 8%, respectively [5]. Corporate Actions - Multiple companies announced share buyback and stake increase plans, with at least 56 A-share listed companies releasing such announcements between April 7 and 8. This included nearly 140 companies disclosing share repurchase plans [15]. - China Aluminum Group and China Minmetals Group both announced plans to increase their stakes in listed companies, with China Aluminum planning to invest between 1 billion to 2 billion RMB [14]. Government and Institutional Support - The "national team" has been actively buying ETFs to stabilize the market, with significant purchases reported from Central Huijin Investment and other state-owned entities [17][21]. - The People's Bank of China indicated readiness to provide sufficient re-lending support to Central Huijin, further emphasizing the commitment to market stability [17]. Investment Outlook - Analysts maintain a relatively optimistic outlook for the A-share market, suggesting that despite uncertainties from trade tensions, the influx of capital and institutional support could lead to a more stable market environment [23]. - The focus on high-quality and high-dividend assets is expected to prevail, with potential opportunities arising from recent market dips [23].

2024 年度持续督导培训的报告 东兴证券股份有限公司(以下简称"东兴证券"或"保荐机构")作为深圳 市易瑞生物技术股份有限公司(以下简称"易瑞生物"或"公司"首次公开发 行股票并在创业板上市以及向不特定对象发行可转换公司债券的保荐机构,根据 《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司自律监管指引第 13 号 -- 保荐业务》等有关法律法规的规定,对易瑞生物的控股股东、实际控 制人、董事、监事、高级管理人员、中层以上管理人员等相关人员进行了 2024 年度持续督导现场培训,现将培训情况报告如下: 一、本次培训的基本情况 东兴证券股份有限公司 关于深圳市易瑞生物技术股份有限公司 2025年4月2日,东兴证券保荐代表人周磊和付书博在易瑞生物会议室对 公司控股股东、实际控制人、董事、监事、高级管理人员、中层以上管理人员等 相关人员进行了沟通及培训。 二、参加本次培训的人员 公司控股股东、实际控制人、董事、监事、高级管理人员、中层以上管理人 员等相关人员。 三、本次培训内容 保荐代表人向被培训人员展示了培训课件,通过现场讲解及交流的方式就上 市公司信息披露重要性、实际控制人、董监高行为规范以及募集资金管 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-006 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于 2025 年第一季度可转债转股情况的公告 1、证券代码：300942 证券简称：易瑞生物 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，深圳市易瑞生物技术 股份有限公司（以下简称"公司"）现将 2025 年第一季度可转换公司债券（以 下简称"可转债"）转股及公司总股本变化情况公告如下： 一、可转债基本情况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意深圳市易瑞生物技术股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1447 号）同意 注册，公司于 2023 年 8 月 18 日向不特定对象发行可转债 3,281,967 张，每张面 值为人民币 100.00 元，发行总额为人民币 328,196,700 元，期限为 6 年。 （二）可转债上市情况 本公司及董事会全体成员保 ...

中国经济网北京3月20日讯 易瑞生物(300942.SZ)昨晚发布的关于部分股东减持股份的预披露公告显示， 公司控股股东、实际控制人的一致行动人深圳易达瑞管理咨询合伙企业（有限合伙）（简称"易达瑞"） 和深圳易凯瑞管理咨询合伙企业（有限合伙）（简称"易凯瑞"），以及持股5%以上股东王天一计划在 公告披露之日起15个交易日后的3个月内（即2025年4月11日至2025年7月10日期间）以集中竞价或大宗 交易方式减持公司股份。 易瑞生物表示，本次股份减持计划系股东的正常减持行为，不会对公司治理结构、股权结构及未来持续 经营产生重大影响，也不会导致公司控制权发生变更。 持有公司股份19,419,203股（占公司总股本1的4.8443%）的股东易达瑞计划以集中竞价交易或大宗交易 的方式减持其持有的公司股份合计不超过411,200股（占公司总股本的0.1026%）。 持有公司股份23,152,903股（占公司总股本的5.7757%）的股东易凯瑞计划以集中竞价交易或大宗交易 的方式减持其持有的公司股份合计不超过575,700股（占公司总股本的0.1436%）。 持有公司股份26,403,521股（占公司总股本的6.586 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-005 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 关于部分股东减持股份的预披露公告 公司控股股东、实际控制人的一致行动人深圳易达瑞管理咨询合伙企业（有 限合伙）和深圳易凯瑞管理咨询合伙企业（有限合伙），以及持股 5%以上股东 王天一先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 深圳市易瑞生物技术股份有限公司（以下简称"公司"或"本公司"）控股 股东、实际控制人的一致行动人深圳易达瑞管理咨询合伙企业（有限合伙）（以 下简称"易达瑞"）和深圳易凯瑞管理咨询合伙企业（有限合伙）（以下简称"易 凯瑞"），以及持股 5%以上股东王天一先生计划在本公告披露之日起 15 个交易 日后的 3 个月内（即 2025 年 4 月 11 日至 2025 年 7 月 10 日期间）以集中竞价或 大宗交易方式减持公司股份，具体情况如下： 深圳市易瑞生物技术股份有限公司 1、持有公司股份 19,419 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 编号：2025-004 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 投资者关系活动记录表 | 投资者关系活 | 特定对象调研 分析师会议 |  | | --- | --- | --- | | 动类别 | 媒体采访 业绩说明会 | | | | 新闻发布会 路演活动 | | | | 现场参观 其他 | | | 参与单位名称 | 初华资本有限公司 李献红 | | | | 必达控股集团有限公司 方建成 | | | | 深圳市凯丰投资管理有限公司 童帅 | | | | 华西证券有限公司 董远 | | | | 第一创业资管 杜欢欢 | | | 及人员姓名 | 嘉实基金管理有限公司 杨健 | | | | 海通证券股份有限公司 敖健 | | | | 民生加银基金 付裕 | | | | 景顺长城基金 方铃亚 | | | 时间 | 2025 年 3 月 13 日 13:45-15:30 | | | 地点 | 公司会议室 | | | 上市公司接待 | 子公司爱医生物执行 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 编号：2025-003 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 投资者关系活动记录表 | 投资者关系活 |  特定对象调研 分析师会议 | | | | | | --- | --- | --- | --- | --- | --- | | 动类别 | 媒体采访 业绩说明会 | | | | | | | 新闻发布会 路演活动 | | | | | | | 现场参观 其他 | | | | | | 参与单位名称 | 英大证券有限责任公司 汪瀚 | | | | | | | 深圳市中肯私募基金管理公司 邓家淇 | | | | | | | 招商证券股份有限公司 刘豪 | | | | | | | 林远涛 | | | 深圳高平聚能资本管理有限公司 | | | | 深圳市丰坤资本投资有限公司 徐标标 | | | | | | 及人员姓名 | | | | | 深圳民沣私募证券投资基金管理有限公司 黄海山 | | | 北方亚事资产评估有限责任公司 郑传国 | | | | | ...